Gabather (GABA) Investor Update summary

Company overview and focus

• Specializes in therapies for mental health disorders, targeting the GABA neurotransmitter system.

• Listed on Nasdaq First North since 2018, with compounds originating from research at Lund University and Sankt Hans Hospital.

• Pipeline centers on GABA A receptor modulators, with GT002 as the lead asset.

Lead asset GT002 and clinical progress

• GT002 is a potent, selective, orally available, and well-tolerated small molecule with no sedative effects.

• Completed three successful phase I studies in healthy volunteers; now entering phase II for cognitive impairment in schizophrenia.

• Demonstrated stability for four years and strong intellectual property protection.

• Uses advanced imaging (EEG, fMRI) to track drug effects on cognition and neural fingerprints.

Market opportunity and innovation

• Addresses large unmet needs in CNS disorders, including schizophrenia, Alzheimer's, ADHD, and autism.

• GT002 could be the first biomarker-driven drug for cognitive impairment in schizophrenia.

• Potential for licensing deals, co-development, and clinical collaborations with major pharma companies.

• Comparable deals in the sector suggest significant potential value for GT002 agreements.